Pediatric Brain Tumors: Current Treatment Strategies and Future Therapeutic Approaches

Neurotherapeutics

Volumn 6, Issue 3, 2009, Pages 570-586

  Mueller, Sabine ^a   Chang, Susan ^a  

^a UNIVERSITY OF SAN FRANCISCO   (United States)

Author keywords

astrocytoma; ependymoma; medulloblastoma; Pediatric brain tumor; primitive neuroectodermal tumors; therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CEDIRANIB; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; ERLOTINIB; ETOPOSIDE; EVEROLIMUS; GDC 0449; IFOSFAMIDE; IMATINIB; IRINOTECAN; ISOTRETINOIN; LOMUSTINE; METHOTREXATE; MK 0752; NITROSOUREA; PREDNISONE; PROCARBAZINE; RETINOIC ACID; TEMOZOLOMIDE; THIOTEPA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; VORINOSTAT;

ADJUVANT THERAPY; ARTICLE; ASTROCYTOMA; BRAIN HEMORRHAGE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHILDHOOD CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIFFUSE BRAIN STEM GLIOMA; DRUG ACTIVITY; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; EPENDYMOMA; GLIOBLASTOMA; GLIOMA; HUMAN; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NEUROECTODERM TUMOR; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; SUPRATENTORIAL NEUROECTODERM TUMOR;

ANIMALS; ASTROCYTOMA; BRAIN NEOPLASMS; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; DRUG THERAPY; EPENDYMOMA; GLIOMA; HUMANS; MEDULLOBLASTOMA; NEOPLASM STAGING; NEUROECTODERMAL TUMORS; NEUROSURGICAL PROCEDURES; RADIOTHERAPY;

EID: 67649097433     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2009.04.006     Document Type: Article

References (172)

1. Kagawa N., Maruno M., Suzuki T., et al. Detection of genetic and chromosomal aberrations in medulloblastomas and primitive neuroectodermal tumors with DNA microarrays. Brain Tumor Pathol 23 (2006) 41-47
2. Nicholson J.C., Ross F.M., Kohler J.A., and Ellison D.W. Comparative genomic hybridization and histological variation in primitive neuroectodermal tumours. Br J Cancer 80 (1999) 1322-1331
3. Pomeroy S.L., Tamayo P., Gaasenbeek M., et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415 (2002) 436-442
4. Russo C., Pellarin M., Tingby O., et al. Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer 86 (1999) 331-339
5. Albright A.L., Wisoff J.H., Zeltzer P.M., et al. Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group. Neurosurgery 38 (1996) 265-271
6. Grill J., Sainte-Rose C., Jouvet A., et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol 6 (2005) 573-580
7. Zeltzer P.M., Boyett J.M., Finlay J.L., et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol 17 (1999) 832-845
8. Lee M., Wisoff J.H., Abbott R., Freed D., and Epstein F.J. Management of hydrocephalus in children with medulloblastoma: prognostic factors for shunting. Pediatr Neurosurg 20 (1994) 240-247
9. Robertson P.L., Muraszko K.M., Holmes E.J., et al. Incidence and severity of postoperative cerebellar mutism syndrome in children with medulloblastoma: a prospective study by the Children's Oncology Group. J Neurosurg 105 (2006) 444-451
10. Doxey D., Bruce D., Sklar F., Swift D., and Shapiro K. Posterior fossa syndrome: identifiable risk factors and irreversible complications. Pediatr Neurosurg 31 (1999) 131-136
11. Turgut M. Transient "cerebellar" mutism. Childs Nerv Syst 14 (1998) 161-166
12. Adachi J., Nishikawa R., Hirose T., and Matsutani M. Mixed neuronal-glial tumor of the fourth ventricle and successful treatment of postoperative mutism with bromocriptine: case report. Surg Neurol 63 (2005) 375-379
13. Mateo-Sierra O., Gutierrez F.A., Fernandez-Carballal C., et al. [Akinetic mutism related to hydrocephalus and cerebellar surgery treated with bromocriptine and ephedrine. A pathophysiological review]. Neurocirugia (Astur) 16 (2005) 134-141
14. Grau C., and Overgaard J. Postirradiation sensorineural hearing loss: a common but ignored late radiation complication. Int J Radiat Oncol Biol Phys 36 (1996) 515-517
15. Plowman P.N. Post-radiation sensorineuronal hearing loss. Int J Radiat Oncol Biol Phys 52 (2002) 589-591
16. Merchant T.E., Kiehna E.N., Li C., et al. Modeling radiation dosimetry to predict cognitive outcomes in pediatric patients with CNS embryonal tumors including medulloblastoma. Int J Radiat Oncol Biol Phys 65 (2006) 210-221
17. Ricardi U., Corrias A., Einaudi S., et al. Thyroid dysfunction as a late effect in childhood medulloblastoma: a comparison of hyperfractionated versus conventionally fractionated craniospinal radiotherapy. Int J Radiat Oncol Biol Phys 50 (2001) 1287-1294
18. Bowers D.C., Liu Y., Leisenring W., et al. Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol 24 (2006) 5277-5282
19. Neglia J.P., Robison L.L., Stovall M., et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 98 (2006) 1528-1537
20. Deutsch M., Thomas P.R., Krischer J., et al. Results of a prospective randomized trial comparing standard dose neuraxis irradiation (3,600 cGy/20) with reduced neuraxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma. A Combined Children's Cancer Group-Pediatric Oncology Group Study. Pediatr Neurosurg 24 (1996) 167-176
21. Thomas P.R., Deutsch M., Kepner J.L., et al. Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. J Clin Oncol 18 (2000) 3004-3011
22. Merchant T.E., Kun L.E., Krasin M.J., et al. Multi-institution prospective trial of reduced-dose craniospinal irradiation (23.4 Gy) followed by conformal posterior fossa (36 Gy) and primary site irradiation (55.8 Gy) and dose-intensive chemotherapy for average-risk medulloblastoma. Int J Radiat Oncol Biol Phys 70 (2008) 782-787
23. Wolden S.L., Dunkel I.J., Souweidane M.M., et al. Patterns of failure using a conformal radiation therapy tumor bed boost for medulloblastoma. J Clin Oncol 21 (2003) 3079-3083
24. Abe M., Tokumaru S., Tabuchi K., et al. Stereotactic radiation therapy with chemotherapy in the management of recurrent medulloblastomas. Pediatr Neurosurg 42 (2006) 81-88
25. Hodgson D.C., Goumnerova L.C., Loeffler J.S., et al. Radiosurgery in the management of pediatric brain tumors. Int J Radiat Oncol Biol Phys 50 (2001) 929-935
26. Milker-Zabel S., Zabel A., Thilmann C., et al. Results of three-dimensional stereotactically-guided radiotherapy in recurrent medulloblastoma. J Neurooncol 60 (2002) 227-233
27. Packer R.J., Gajjar A., Vezina G., et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 24 (2006) 4202-4208
28. Packer R.J., Goldwein J., Nicholson H.S., et al. Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A Children's Cancer Group Study. J Clin Oncol 17 (1999) 2127-2136
29. Kortmann R.D., Kuhl J., Timmermann B., et al. Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the German prospective randomized trial HIT '91. Int J Radiat Oncol Biol Phys 46 (2000) 269-279
30. Taylor R.E., Bailey C.C., Robinson K., et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol 21 (2003) 1581-1591
31. Taylor R.E., Bailey C.C., Robinson K.J., et al. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. Eur J Cancer 41 (2005) 727-734
32. Okada S., Hongo T., Sakaguchi K., et al. Pilot study of ifosfamide/carboplatin/etoposide (ICE) for peripheral blood stem cell mobilization in patients with high-risk or relapsed medulloblastoma. Childs Nerv Syst 23 (2007) 407-413
33. Strother D., Ashley D., Kellie S.J., et al. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma or supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: results of a collaborative study. J Clin Oncol 19 (2001) 2696-2704
34. Gajjar A., Chintagumpala M., Ashley D., et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 7 (2006) 813-820
35. Jakacki R., Burger P., Zhou T., et al. Outcome for metastatic (M+) medulloblastoma (MB) treated with carboplatin during craniospinal radiotherapy (CSRT) followed by cyclophosphamide (CPM) and vincristine (VCR): Preliminary results of COG 99701. Journal of Clinical Oncology 25 (2007) 2017
36. Evans A.E., Jenkin R.D., Sposto R., et al. The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone. J Neurosurg 72 (1990) 572-582
37. Rutkowski S., Bode U., Deinlein F., et al. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 352 (2005) 978-986
38. van Eys J., Cangir A., Coody D., and Smith B. MOPP regimen as primary chemotherapy for brain tumors in infants. J Neurooncol 3 (1985) 237-243
39. Duffner P.K., Horowitz M.E., Krischer J.P., et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328 (1993) 1725-1731
40. Geyer J.R., Zeltzer P.M., Boyett J.M., et al. Survival of infants with primitive neuroectodermal tumors or malignant ependymomas of the CNS treated with eight drugs in 1 day: a report from the Childrens Cancer Group. J Clin Oncol 12 (1994) 1607-1615
41. Geyer J.R., Sposto R., Jennings M., et al. Multiagent chemotherapy and deferred radiotherapy in infants with malignant brain tumors: a report from the Children's Cancer Group. J Clin Oncol 23 (2005) 7621-7631
42. Mason W.P., Grovas A., Halpern S., et al. Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 16 (1998) 210-221
43. Chi S.N., Gardner S.L., Levy A.S., et al. Feasibility and response to induction chemotherapy intensified with high-dose methotrexate for young children with newly diagnosed high-risk disseminated medulloblastoma. J Clin Oncol 22 (2004) 4881-4887
44. Michaelis J., Kaletsch U., and Kaatsch P. [Epidemiology of childhood brain tumors]. Zentralbl Neurochir 61 (2000) 80-87
45. Pollack I.F. Brain tumors in children. N Engl J Med 331 (1994) 1500-1507
46. Johnston D.L., Keene D.L., Lafay-Cousin L., et al. Supratentorial primitive neuroectodermal tumors: a Canadian pediatric brain tumor consortium report. J Neurooncol 86 (2008) 101-108
47. Chang C.H., Housepian E.M., and Herbert Jr. C. An operative staging system and a megavoltage radiotherapeutic technic for cerebellar medulloblastomas. Radiology 93 (1969) 1351-1359
48. Albright A.L., Wisoff J.H., Zeltzer P., et al. Prognostic factors in children with supratentorial (nonpineal) primitive neuroectodermal tumors. A neurosurgical perspective from the Children's Cancer Group. Pediatr Neurosurg 22 (1995) 1-7
49. Ashwal S., Hinshaw Jr. D.B., and Bedros A. CNS primitive neuroectodermal tumors of childhood. Med Pediatr Oncol 12 (1984) 180-188
50. Dirks P.B., Harris L., Hoffman H.J., et al. Supratentorial primitive neuroectodermal tumors in children. J Neurooncol 29 (1996) 75-84
51. MacDonald T.J. Aggressive infantile embryonal tumors. J Child Neurol 23 (2008) 1195-1204
52. Reddy A.T., Janss A.J., Phillips P.C., Weiss H.L., and Packer R.J. Outcome for children with supratentorial primitive neuroectodermal tumors treated with surgery, radiation, and chemotherapy. Cancer 88 (2000) 2189-2193
53. Massimino M., Gandola L., Spreafico F., et al. Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy. Int J Radiat Oncol Biol Phys 64 (2006) 1031-1037
54. Timmermann B., Kortmann R.D., Kuhl J., et al. Role of radiotherapy in the treatment of supratentorial primitive neuroectodermal tumors in childhood: results of the prospective German brain tumor trials HIT 88/89 and 91. J Clin Oncol 20 (2002) 842-849
55. Marec-Berard P., Jouvet A., Thiesse P., et al. Supratentorial embryonal tumors in children under 5 years of age: an SFOP study of treatment with postoperative chemotherapy alone. Med Pediatr Oncol 38 (2002) 83-90
56. McBride S.M., Daganzo S.M., Banerjee A., et al. Radiation is an important component of multimodality therapy for pediatric non-pineal supratentorial primitive neuroectodermal tumors. Int J Radiat Oncol Biol Phys 72 (2008) 1319-1323
57. Jakacki R.I., Zeltzer P.M., Boyett J.M., et al. Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: a report of the Childrens Cancer Group. J Clin Oncol 13 (1995) 1377-1383
58. Gururangan S., McLaughlin C., Quinn J., et al. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. J Clin Oncol 21 (2003) 2187-2191
59. Pizer B.L., Weston C.L., Robinson K.J., et al. Analysis of patients with supratentorial primitive neuro-ectodermal tumours entered into the SIOP/UKCCSG PNET 3 study. Eur J Cancer 42 (2006) 1120-1128
60. Broniscer A., Nicolaides T.P., Dunkel I.J., et al. High-dose chemotherapy with autologous stem-cell rescue in the treatment of patients with recurrent non-cerebellar primitive neuroectodermal tumors. Pediatr Blood Cancer 42 (2004) 261-267
61. Fangusaro J., Finlay J., Sposto R., et al. Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): report of the Head Start I and II experience. Pediatr Blood Cancer 50 (2008) 312-318
62. Chintagumpala M., Hassall T., Palmer S., et al. A pilot study of risk-adapted radiotherapy and chemotherapy in patients with supratentorial PNET. Neuro Oncol 11 (2009) 33-40
63. Fernandez-Teijeiro A., Betensky R.A., Sturla L.M., et al. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol 22 (2004) 994-998
64. Fattet S., Haberler C., Legoix P., et al. Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 218 (2009) 86-94
65. Grotzer M.A., Janss A.J., Fung K., et al. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 18 (2000) 1027-1035
66. Grotzer M.A., Janss A.J., Phillips P.C., and Trojanowski J.Q. Neurotrophin receptor TrkC predicts good clinical outcome in medulloblastoma and other primitive neuroectodermal brain tumors. Klin Padiatr 212 (2000) 196-199
67. Segal R.A., Goumnerova L.C., Kwon Y.K., Stiles C.D., and Pomeroy S.L. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A 91 (1994) 12867-12871
68. Eberhart C.G., Kratz J., Wang Y., et al. Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol 63 (2004) 441-449
69. Grotzer M.A., Hogarty M.D., Janss A.J., et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 7 (2001) 2425-2433
70. Herms J., Neidt I., Luscher B., et al. C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 89 (2000) 395-402
71. Rutkowski S., von Bueren A., von Hoff K., et al. Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT′91. Clin Cancer Res 13 (2007) 2651-2657
72. Di C., Liao S., Adamson D.C., et al. Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res 65 (2005) 919-924
73. Berman D.M., Karhadkar S.S., Hallahan A.R., et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 297 (2002) 1559-1561
74. Fan X., Matsui W., Khaki L., et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 66 (2006) 7445-7452
75. Romer J.T., Kimura H., Magdaleno S., et al. Suppression of the SHH pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1(+/-)p53(-/-) mice. Cancer Cell 6 (2004) 229-240
76. Guerreiro A.S., Fattet S., Fischer B., et al. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. Clin Cancer Res 14 (2008) 6761-6769
77. Hambardzumyan D., Becher O.J., Rosenblum M.K., et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 22 (2008) 436-448
78. Hartmann W., Digon-Sontgerath B., Koch A., et al. Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res 12 (2006) 3019-3027
79. Hallahan A.R., Pritchard J.I., Chandraratna R.A., et al. BMP-2 mediates retinoid-induced apoptosis in medulloblastoma cells through a paracrine effect. Nat Med 9 (2003) 1033-1038
80. Spiller S.E., Ditzler S.H., Pullar B.J., and Olson J.M. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J Neurooncol 87 (2008) 133-141
81. Pollack I.F., Finkelstein S.D., Woods J., et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346 (2002) 420-427
82. Campbell J.W., Pollack I.F., Martinez A.J., and Shultz B. High-grade astrocytomas in children: radiologically complete resection is associated with an excellent long-term prognosis. Neurosurgery 38 (1996) 258-264
83. Finlay J.L., Boyett J.M., Yates A.J., et al. Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol 13 (1995) 112-123
84. Wisoff J.H., Boyett J.M., Berger M.S., et al. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg 89 (1998) 52-59
85. Wolff J.E., Gnekow A.K., Kortmann R.D., et al. Preradiation chemotherapy for pediatric patients with high-grade glioma. Cancer 94 (2002) 264-271
86. Fulton D.S., Urtasun R.C., Scott-Brown I., et al. Increasing radiation dose intensity using hyperfractionation in patients with malignant glioma. Final report of a prospective phase I-II dose response study. J Neurooncol 14 (1992) 63-72
87. Sposto R., Ertel I.J., Jenkin R.D., et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group. J Neurooncol 7 (1989) 165-177
88. Finlay J.L., and Zacharoulis S. The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical - and futuristic - perspective. J Neurooncol 75 (2005) 253-266
89. Pollack I.F., Boyett J.M., Yates A.J., et al. The influence of central review on outcome associations in childhood malignant gliomas: results from the CCG-945 experience. Neuro Oncol 5 (2003) 197-207
90. MacDonald T.J., Arenson E.B., Ater J., et al. Phase II study of high-dose chemotherapy before radiation in children with newly diagnosed high-grade astrocytoma: final analysis of Children's Cancer Group Study 9933. Cancer 104 (2005) 2862-2871
91. Chastagner P., Kalifa C., Doz F., et al. Outcome of children treated with preradiation chemotherapy for a high-grade glioma: results of a French Society of Pediatric Oncology (SFOP) Pilot Study. Pediatr Blood Cancer 49 (2007) 803-807
92. Estlin E.J., Lashford L., Ablett S., et al. Phase I study of temozolomide in paediatric patients with advanced cancer. United Kingdom Children's Cancer Study Group. Br J Cancer 78 (1998) 652-661
93. Lashford L.S., Thiesse P., Jouvet A., et al. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J Clin Oncol 20 (2002) 4684-4691
94. Nicholson H.S., Kretschmar C.S., Krailo M., et al. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. Cancer 110 (2007) 1542-1550
95. Vredenburgh J.J., Desjardins A., Herndon II J.E., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13 (2007) 1253-1259
96. Broniscer A., Baker S.J., Stewart C.F., et al. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res 15 (2009) 701-707
97. Pollack I.F., Jakacki R.I., Blaney S.M., et al. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro Oncol 9 (2007) 145-160
98. Laws Jr. E.R., Taylor W.F., Clifton M.B., and Okazaki H. Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg 61 (1984) 665-673
99. Pollack I.F., Claassen D., al-Shboul Q., Janosky J.E., and Deutsch M. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. J Neurosurg 82 (1995) 536-547
100. Schneider Jr. J.H., Raffel C., and McComb J.G. Benign cerebellar astrocytomas of childhood. Neurosurgery 30 (1992) 58-62
101. Benesch M., Eder H.G., Sovinz P., et al. Residual or recurrent cerebellar low-grade glioma in children after tumor resection: is re-treatment needed?. A single center experience from 1983 to 2003. Pediatr Neurosurg 42 (2006) 159-164
102. Garcia D.M., Marks J.E., Latifi H.R., and Kliefoth A.B. Childhood cerebellar astrocytomas: is there a role for postoperative irradiation?. Int J Radiat Oncol Biol Phys 18 (1990) 815-818
103. Watson G.A., Kadota R.P., and Wisoff J.H. Multidisciplinary management of pediatric low-grade gliomas. Semin Radiat Oncol 11 (2001) 152-162
104. Listernick R., Darling C., Greenwald M., Strauss L., and Charrow J. Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history. J Pediatr 127 (1995) 718-722
105. Fouladi M., Hunt D.L., Pollack I.F., et al. Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Children's Cancer Group high-grade glioma study CCG-945. Cancer 98 (2003) 1243-1252
106. Mishra K.K., Puri D.R., Missett B.T., et al. The role of up-front radiation therapy for incompletely resected pediatric WHO grade II low-grade gliomas. Neuro Oncol 8 (2006) 166-174
107. Marcus K.J., Goumnerova L., Billett A.L., et al. Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial. Int J Radiat Oncol Biol Phys 61 (2005) 374-379
108. Packer R.J., Lange B., Ater J., et al. Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 11 (1993) 850-856
109. Packer R.J., Ater J., Allen J., et al. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 86 (1997) 747-754
110. Perilongo G. Considerations on the role of chemotherapy and modern radiotherapy in the treatment of childhood low grade glioma. J Neurooncol 75 (2005) 301-307
111. Massimino M., Spreafico F., Cefalo G., et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol 20 (2002) 4209-4216
112. Gururangan S., Cavazos C.M., Ashley D., et al. Phase II study of carboplatin in children with progressive low-grade gliomas. J Clin Oncol 20 (2002) 2951-2958
113. Kuo D.J., Weiner H.L., Wisoff J., et al. Temozolomide is active in childhood, progressive, unresectable, low-grade gliomas. J Pediatr Hematol Oncol 25 (2003) 372-378
114. Cheng Y., Pang J.C., Ng H.K., et al. Pilocytic astrocytomas do not show most of the genetic changes commonly seen in diffuse astrocytomas. Histopathology 37 (2000) 437-444
115. Bigner S.H., McLendon R.E., Fuchs H., McKeever P.E., and Friedman H.S. Chromosomal characteristics of childhood brain tumors. Cancer Genet Cytogenet 97 (1997) 125-134
116. Orr L.C., Fleitz J., McGavran L., et al. Cytogenetics in pediatric low-grade astrocytomas. Med Pediatr Oncol 38 (2002) 173-177
117. Sanoudou D., Tingby O., Ferguson-Smith M.A., Collins V.P., and Coleman N. Analysis of pilocytic astrocytoma by comparative genomic hybridization. Br J Cancer 82 (2000) 1218-1222
118. Jones D.T., Ichimura K., Liu L., et al. Genomic analysis of pilocytic astrocytomas at 0.97 Mb resolution shows an increasing tendency toward chromosomal copy number change with age. J Neuropathol Exp Neurol 65 (2006) 1049-1058
119. Zattara-Cannoni H., Gambarelli D., Lena G., et al. Are juvenile pilocytic astrocytomas benign tumors?. A cytogenetic study in 24 cases. Cancer Genet Cytogenet 104 (1998) 157-160
120. Pfister S., Janzarik W.G., Remke M., et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 118 (2008) 1739-1749
121. Bar E.E., Lin A., Tihan T., Burger P.C., and Eberhart C.G. Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol 67 (2008) 878-887
122. Jones D.T., Kocialkowski S., Liu L., et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 68 (2008) 8673-8677
123. Chico-Ponce de Leon F., Perezpena-Diazconti M., Castro-Sierra E., et al. Stereotactically-guided biopsies of brainstem tumors. Childs Nerv Syst 19 (2003) 305-310
124. Roujeau T., Machado G., Garnett M.R., et al. Stereotactic biopsy of diffuse pontine lesions in children. J Neurosurg 107 (2007) 1-4
125. Sanford R.A., Freeman C.R., Burger P., and Cohen M.E. Prognostic criteria for experimental protocols in pediatric brainstem gliomas. Surg Neurol 30 (1988) 276-280
126. Zagzag D., Miller D.C., Knopp E., et al. Primitive neuroectodermal tumors of the brainstem: investigation of seven cases. Pediatrics 106 (2000) 1045-1053
127. Freeman C.R., and Farmer J.P. Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys 40 (1998) 265-271
128. Haas-Kogan D.A., Banerjee A., Kocak M., et al. Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma. Neuro Oncol 10 (2008) 341-347
129. Albright A.L., Packer R.J., Zimmerman R., et al. Magnetic resonance scans should replace biopsies for the diagnosis of diffuse brain stem gliomas: a report from the Children's Cancer Group. Neurosurgery 33 (1993) 1026-1029 discussion 1029-1030
130. Epstein F., and Constantini S. Practical decisions in the treatment of pediatric brain stem tumors. Pediatr Neurosurg 24 (1996) 24-34
131. Packer R.J., Boyett J.M., Zimmerman R.A., et al. Outcome of children with brain stem gliomas after treatment with 7800 cGy of hyperfractionated radiotherapy. A Childrens Cancer Group Phase I/II Trial. Cancer 74 (1994) 1827-1834
132. Freeman C.R., Krischer J.P., Sanford R.A., et al. Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys 27 (1993) 197-206
133. Mandell L.R., Kadota R., Freeman C., et al. There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 43 (1999) 959-964
134. Jennings M.T., Sposto R., Boyett J.M., et al. Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group. J Clin Oncol 20 (2002) 3431-3437
135. Freeman C.R., Kepner J., Kun L.E., et al. A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas?. Int J Radiat Oncol Biol Phys 47 (2000) 561-564
136. Bouffet E., Raquin M., Doz F., et al. Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer 88 (2000) 685-692
137. Dunkel I.J., O'Malley B., and Finlay J.L. Is there a role for high-dose chemotherapy with stem cell rescue for brain stem tumors of childhood?. Pediatr Neurosurg 24 (1996) 263-266
138. Finlay J.L. The role of high-dose chemotherapy and stem cell rescue in the treatment of malignant brain tumors. Bone Marrow Transplant 18 suppl 3 (1996) S1-S5
139. Frappaz D., Schell M., Thiesse P., et al. Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: final results of BSG 98 prospective trial. Neuro Oncol 10 (2008) 599-607
140. Sirachainan N., Pakakasama S., Visudithbhan A., et al. Concurrent radiotherapy with temozolomide followed by adjuvant temozolomide and cis-retinoic acid in children with diffuse intrinsic pontine glioma. Neuro Oncol 10 (2008) 577-582
141. Hargrave D., Bartels U., and Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7 (2006) 241-248
142. Hargrave D., Chuang N., and Bouffet E. Conventional MRI cannot predict survival in childhood diffuse intrinsic pontine glioma. J Neurooncol 86 (2008) 313-319
143. Daw N.C., Furman W.L., Stewart C.F., et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 23 (2005) 6172-6180
144. Freeman III B.B., Daw N.C., Geyer J.R., Furman W.L., and Stewart C.F. Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest 24 (2006) 310-317
145. Packer R.J., Krailo M., Mehta M., et al. A Phase I study of concurrent RMP-7 and carboplatin with radiation therapy for children with newly diagnosed brainstem gliomas. Cancer 104 (2005) 1968-1974
146. Ross G.W., and Rubinstein L.J. Lack of histopathological correlation of malignant ependymomas with postoperative survival. J Neurosurg 70 (1989) 31-36
147. Bouffet E., Perilongo G., Canete A., and Massimino M. Intracranial ependymomas in children: a critical review of prognostic factors and a plea for cooperation. Med Pediatr Oncol 30 (1998) 319-329 discussion 329-331
148. Robertson P.L., Zeltzer P.M., Boyett J.M., et al. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg 88 (1998) 695-703
149. McGuire C.S., Sainani K.L., and Fisher P.G. Both location and age predict survival in ependymoma: a SEER study. Pediatr Blood Cancer 52 (2009) 65-69
150. Timmermann B., Kortmann R.D., Kuhl J., et al. Combined postoperative irradiation and chemotherapy for anaplastic ependymomas in childhood: results of the German prospective trials HIT 88/89 and HIT 91. Int J Radiat Oncol Biol Phys 46 (2000) 287-295
151. Goldwein J.W., Corn B.W., Finlay J.L., et al. Is craniospinal irradiation required to cure children with malignant (anaplastic) intracranial ependymomas?. Cancer 67 (1991) 2766-2771
152. Merchant T.E., Mulhern R.K., Krasin M.J., et al. Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 22 (2004) 3156-3162
153. Rousseau P., Habrand J.L., Sarrazin D., et al. Treatment of intracranial ependymomas of children: review of a 15-year experience. Int J Radiat Oncol Biol Phys 28 (1994) 381-386
154. MacDonald S.M., Safai S., Trofimov A., et al. Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. Int J Radiat Oncol Biol Phys 71 (2008) 979-986
155. McLaughlin M.P., Marcus Jr. R.B., Buatti J.M., et al. Ependymoma: results, prognostic factors and treatment recommendations. Int J Radiat Oncol Biol Phys 40 (1998) 845-850
156. Vanuytsel L., and Brada M. The role of prophylactic spinal irradiation in localized intracranial ependymoma. Int J Radiat Oncol Biol Phys 21 (1991) 825-830
157. Aggarwal R., Yeung D., Kumar P., Muhlbauer M., and Kun L.E. Efficacy and feasibility of stereotactic radiosurgery in the primary management of unfavorable pediatric ependymoma. Radiother Oncol 43 (1997) 269-273
158. Kalapurakal J.A., Goldman S., Stellpflug W., et al. Phase I study of intraoperative radiotherapy with photon radiosurgery system in children with recurrent brain tumors: preliminary report of first dose level (10 Gy). Int J Radiat Oncol Biol Phys 65 (2006) 800-808
159. Grundy R.G., Wilne S.A., Weston C.L., et al. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 8 (2007) 696-705
160. Duffner P.K., Krischer J.P., Sanford R.A., et al. Prognostic factors in infants and very young children with intracranial ependymomas. Pediatr Neurosurg 28 (1998) 215-222
161. Grill J., Le Deley M.C., Gambarelli D., et al. Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. J Clin Oncol 19 (2001) 1288-1296
162. Hargrave D.R., and Zacharoulis S. Pediatric CNS tumors: current treatment and future directions. Expert Rev Neurother 7 (2007) 1029-1042
163. Evans A.E., Anderson J.R., Lefkowitz-Boudreaux I.B., and Finlay J.L. Adjuvant chemotherapy of childhood posterior fossa ependymoma: cranio-spinal irradiation with or without adjuvant CCNU, vincristine, and prednisone: a Childrens Cancer Group study. Med Pediatr Oncol 27 (1996) 8-14
164. Zacharoulis S., Levy A., Chi S.N., et al. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 49 (2007) 34-40
165. Ebert C., von Haken M., Meyer-Puttlitz B., et al. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. Am J Pathol 155 (1999) 627-632
166. Gutmann D.H., Giordano M.J., Fishback A.S., and Guha A. Loss of merlin expression in sporadic meningiomas, ependymomas and schwannomas. Neurology 49 (1997) 267-270
167. Rubio M.P., Correa K.M., Ramesh V., et al. Analysis of the neurofibromatosis 2 gene in human ependymomas and astrocytomas. Cancer Res 54 (1994) 45-47
168. Rajaram V., Gutmann D.H., Prasad S.K., Mansur D.B., and Perry A. Alterations of protein 4.1 family members in ependymomas: a study of 84 cases. Mod Pathol 18 (2005) 991-997
169. Mendrzyk F., Korshunov A., Benner A., et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res 12 (2006) 2070-2079
170. Modena P., Lualdi E., Facchinetti F., et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol 24 (2006) 5223-5233
171. Poppleton H., and Gilbertson R.J. Stem cells of ependymoma. Br J Cancer 96 (2007) 6-10
172. Taylor M.D., Poppleton H., Fuller C., et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8 (2005) 323-335